The Lustgarten Foundation is the largest private funder of pancreatic cancer research in the world.
To date, we’ve invested more than $270M in high-risk, high-reward research to accelerate and expand life-saving treatment options. We lead a unique, collaborative, science-focused strategy and have been a driving force in every major advancement in pancreatic cancer research since 1998.
Progress is paramount. We drive bold, innovative research with the singular mission: transforming pancreatic cancer into a curable disease.
Lustgarten Announcements
Join us for an evening of stunning skyline vistas, unparalleled ambiance, exquisite cocktails and culinary delights – all while supporting groundbreaking pancreatic cancer research.
From devastation to dedication, Gail Coleman is committed to supporting personalized medicine in pancreatic cancer research. WOODBURY, NY, February 14, 2024 – Gail Coleman, a nine-year supporter of the Lustgarten […]
Find a Lustgarten Walk for Pancreatic Cancer Research near you!
News From The Field
On Tuesday, March 12, 2024, we celebrated International Women’s Day at the prestigious Salk Institute for Biological Studies for “The Power of Persistence: Women Transforming Cancer Research & Care.” This […]
With thanks and appreciation to our contributing partner, Let’s Win Pancreatic Cancer. The U.S. Food and Drug Administration has approved irinotecan liposome (ONIVYDE) in combination with oxaliplatin, fluorouracil, and leucovorin, […]
From Lets Win Pancreatic Cancer – The 2025 ASCO Gastrointestinal Cancers Symposium, held from January 18 to 20 in San Francisco, California, once again highlighted the remarkable progress being made […]
SUSAN’s story
From Nurse to Patient
When Susan was diagnosed with pancreatic cancer, cutting-edge drugs and a supportive medical team helped her go from patient to survivor. Now she raises funds for continued research through a Lustgarten Foundation Walk for Research.
Read Susan’s Story![](https://lustgarten.org/wp-content/uploads/2022/02/susan-headshot-553x553.webp)